Wednesday tips round-up: Kazakhmys, Domino's Pizza, Bloomsbury

The biggest drawback at copper miner Kazakhmys for now is that the recent recovery in copper prices ? to which Kazakhmys's fortunes are strongly geared ? means that its near-sevenfold share-price rally since the start of last year could run out of steam. At £15.44, or eight times 2010 earnings, and the dividend yield negligible, the shares are up with events. Pass says the Times.Domino's keeps on delivering. Yesterday's first-quarter update from Britain's biggest dispatcher of pizzas to your door showed like-for-like sales growth of 10.5% in the 13 weeks to March 28 ? on top of a 9.3 % increase in the same period last year ? with total system sales up 17.5 % at £118.9m. The company has a history of generating large amounts of cash and returning it to shareholders through dividends and buybacks. The shares, up 10½p to 345½p, are trading on almost 23 times this year's earnings. Not cheap, but this is a high-quality company that is worth holding says the Times.Drafting Wills in Scotland or Clinical Negligence might not offer the narrative pace of Harry Potter, but they are doing well for Bloomsbury says the Times. But Bloomsbury offers less excitement than other media stocks more geared to cyclical recovery, especially given the £35m of cash on its balance sheet, which dampens returns and makes yesterday's 5% rise in the dividend look rather mean. At 115p, or nine times earnings once the cash is stripped out, pass says the Times.Bloomsbury, the publisher of the Harry Potter series has been expanding its reach into the resilient academic and professional publishing sectors, which will be a defensive buffer against the volatile trade publishing side of the business. The shares are yielding around 4%. At the same time, they trade on an affordable multiple of 13.8 times KBC Peel Hunt's forecasts for 2010. Buy, counters the Independent. Antisoma shares plunged by three-quarters after the group said a phase III trial of its lung-cancer treatment had shown no survival benefit. The treatment will not be developed further. Investor confidence has been shaken and the results of the phase III trials of another drug, AS1413 for acute myeloid leukaemia, will not be released until the end of this year. Sell says the Telegraph.The outsourcing industry says, at least publicly, that this is good thing, and that it will benefit as government looks to save costs. Mouchel, which maintains the motorway network, among other things, reckons it will be in clover as, it says, it will be capital programmes that will be axed rather than spending on maintenance. Mouchel reckons it is a good long to medium-term bet. Hold says the Independent.Afren's portfolio of West African assets should start to throw off a lot of cash from 2011 onwards. Trading on a December 2011 earnings multiple of 5.1, the shares remain a buy. However, investors must consider the inherent risk involved in oil exploration says the Telegraph.Robert Wiseman Dairies drank to a profits upgrade yesterday after a surge in the value of bulk cream in the second half. However, there were some warnings that soured Wiseman's results yesterday, particularly on rising commodity prices. The dairy company said that oil-related costs continued to spike in the second half of the year and the City expects them to remain on an upward trend. Other dark price clouds have emerged in the continued price rises of hydro polyethylene, which it uses for making its plastic cartons. Despite these headwinds,on a fairly valued 2010 price-earnings ratio of 11.5, Wiseman is a healthy choice for long-term shoppers. Buy says the Independent.Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.